Table 5 End-of-treatment and sustained virologic response rates in patients treated to week 48
End-of-treatment response | Patients treated n = 216, n (%) | p* |
|---|---|---|
End-of-treatment Response at week 48, n (%) | 140/216 (64.8%) | Â |
Non-responder to initial treatment | 81/128(63.3%) | 0.671 |
Relapsed to initial treatment | 59/88 (67%) | Â |
Sustained Virologic Response at week 72, n (%) | 88/216 (40.7%) | Â |
Non-responder to initial treatment | 44/128 (34.4%) | 0.031 |
Relapsed to initial treatment | 44/88 (50%) | Â |